124I evuzamitide amyloid PET imaging
phase 3biomarker · high · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Detect cardiac and extracardiac amyloid deposits and support quantitative disease monitoring in systemic amyloidosis.
Amyloid-reactive peptide p5+14 labeled with iodine-124 for PET/CT imaging.
Publication states 124I-evuzamitide has been evaluated in eight investigator-initiated studies and is in the pivotal Phase 3 REVEAL study for detection of cardiac amyloidosis.
A Phase 1/2 study reported uptake consistent with clinical amyloidosis presentation, patient-associated imaging sensitivity of 93.6%, cardiac-associated sensitivity of 96.2%, no cardiac uptake in healthy volunteers, and good tolerability with one drug-related adverse event and no deaths.
99mTc-p5+14 amyloid SPECT imaging
exploratorybiomarker · medium · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Detect cardiac and extracardiac amyloid deposits using a technetium-labeled amyloid-reactive peptide imaging tracer.
Peptide p5+14 labeled with technetium-99m for SPECT/CT imaging of amyloid deposits.
2026 publication compared 99mTc-p5+14 with 124I-evuzamitide as complementary investigational amyloid radiotracers.
Publication reports both tracers image cardiac ATTR and AL amyloidosis, with similar but distinct and complementary image data due to radionuclide characteristics.
p5 CAR macrophage amyloid clearance
preclinicalresearch program · medium · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Engineer macrophages to bind and clear amyloid deposits in systemic amyloidosis.
Chimeric antigen receptor macrophages using a short polybasic p5 peptide recognition motif for pan-amyloid binding and uptake.
2026 Frontiers in Immunology publication described CH2- and CH3-spacer CAR-M designs, glycan interaction quantification, and opsonization- and complement-dependent enhancement.
The study reported that p5 can serve as a versatile recognition motif for CAR macrophages, enabling pan-amyloid binding and uptake and motivating translational studies for systemic amyloidosis.
PxR pan-amyloid binding peptides
preclinicalresearch program · medium · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop amyloid-reactive peptides that can deliver bioactive or amyloid-clearing therapeutics to tissue-deposited amyloid.
Proline-rich, polybasic peptides designed to bind conserved amyloid and amyloid-associated hypersulfated heparan sulfate features with serum stability.
2026 Amyloid journal publication characterized PxR peptides as a structurally distinct class of amyloid-reactive peptides.
PxR peptides showed high specificity and potency for synthetic fibrils and amyloid extracts and resistance to serum proteases in mouse and human serum assays.
AT-02
phase 2drug program · high · Thu Sep 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat systemic amyloidosis by evaluating long-term safety, tolerability, and clinical activity of an investigational medicinal product.
Phase 1 rising single-dose and multiple-dose clinical evaluation followed by Phase 2 open-label extension in healthy volunteers and subjects with systemic amyloidosis.
Phase 2 open-label extension study evaluating long-term safety, tolerability, and clinical activity published on 2023-09-21.
124I AT-01 amyloid PET imaging
phase 1biomarker · high · Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Assess organ-specific amyloid burden and repeatability of radiotracer uptake quantitation in systemic amyloidosis.
124I-labeled amyloid-reactive PET/CT radiotracer imaging in subjects with AL or ATTR systemic amyloidosis.
Clinical trial designed to evaluate organ-level uptake repeatability was published on 2021-11-30.
AT-03 radiolabeled amyloid imaging
phase 1biomarker · high · Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Characterize biodistribution of a radiolabeled amyloid imaging agent in patients with systemic amyloidosis.
Single-center Phase 1 biodistribution study of radiolabeled AT-03.
Phase 1 biodistribution study published on 2021-11-30.
Pan-amyloid removal technology platform
undisclosedplatform · medium
Enable therapeutics and imaging agents that bind conserved amyloid features to remove or detect toxic amyloid across systemic amyloidosis types and stages.
Proprietary pan-amyloid binding/removal technology used to create novel biologics and amyloidosis-specific imaging agents.
Company site states the technology enabled novel biologics and the world's first amyloidosis-specific imaging agent, which was acquired by Bayer.
Zamubafusp Alfa
undiscloseddrug program · medium
Develop a pan-amyloid removal therapeutic intended to bind and remove toxic amyloid deposits in systemic amyloidosis.
Biologic therapeutic listed in Attralus pipeline for amyloid removal across amyloidosis types and stages.
Listed on Attralus pipeline page.
